Search

Résumé Le lupus érythémateux systémique est une maladie auto-immune chronique. À la fois, les systèmes immunitaires acquis et inné interviennent dans le développement de cette affection systémique. La néphrite lupique est habituellement la manifestation la plus sérieuse du lupus érythémateux systémique, grevée d’une morbi-mortalité importante. Le développement physiopathologique de la forme systémique et de l’atteinte rénale du lupus est de mieux en mieux élucidé au fil des années, et diverses approches thérapeutiques dites « ciblées » ont été développées dernièrement. Après quelques rappels physiopathologiques, nous discutons du traitement conventionnel de la néphrite lupique ainsi que des diverses avancées thérapeutiques, en particulier l’apport et la place des nouvelles thérapies ciblées dans le traitement de la néphrite lupique. Systemic lupus erythematosus is a chronic autoimmune disease. Both acquired and innate immune systems are involved in the development of this systemic disease. Lupus nephritis usually is the most serious manifestation of systemic lupus erythematosus, with significant morbidity and mortality. The physiopathological development of the renal involvement of lupus has been increasingly elucidated over the years and various target therapies have recently been developed. After some physiopathological reminders, we discuss the conventional treatment of lupus nephritis as well as the various therapeutic advances, in particular the contribution and the place of the new target therapies in the treatment of the lupus nephritis. [ABSTRACT FROM AUTHOR]

In this article we shall discuss the subject of target therapies concerning squamous cell carcinoma of the head and neck. Indeed, taking into account the molecular modifications generated by the carcinogenesis of squamous cell carcinoma of the head and neck, new treatment strategies have been developed and have joined the arsenal of conventional chemotherapy and radiotherapy. These new molecules target the molecular alterations and block the metabolic tracts by acting on the tumoral progression. The leader is the receptor for EGF (the EGFR). [ABSTRACT FROM AUTHOR]

Systemic lupus erythematosus is a chronic autoimmune disease. Both acquired and innate immune systems are involved in the development of this systemic disease. Lupus nephritis usually is the most serious manifestation of systemic lupus erythematosus, with significant morbidity and mortality. The physiopathological development of the renal involvement of lupus has been increasingly elucidated over the years and various target therapies have recently been developed. After some physiopathological reminders, we discuss the conventional treatment of lupus nephritis as well as the various therapeutic advances, in particular the contribution and the place of the new target therapies in the treatment of the lupus nephritis., (Copyright © 2017 Société francophone de néphrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.)